Concordance Between Fingerprick and Venous Whole Blood CD4 Counts Using the Visitect CD4 Advanced disease platform.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 42636100.
- Also identified by DOI 10.1093/infdis/jiag437.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The Visitect CD4 Advanced Disease platform is a rapid, semi-quantitative assay that estimates CD4 results above or below 200 cells/μL and can be performed on venous whole blood or by fingerprick. We conducted a prospective validation of the Visitect CD4 Advanced Disease platform via fingerprick versus venous whole blood. Overall, there was 95.5% agreement (149/156). The high level of agreement between the fingerprick and venous whole blood results may support the use of the fingerprick Visitect CD4 test as a reliable point-of-care diagnostic tool in settings where access to conventional venous whole blood testing may be limited.